LBA9508Background: Optimal first line therapy for patients with metastatic melanoma is an immunotherapy regimen containing an anti-PD1 antibody, regardless of tumour BRAF mutation status. Anti-PD1 ...

Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.

PURPOSEAs the complexity and need for cancer care services continue to grow, time to treatment initiation (TTI) has been increasing across cancer types. Presently there are no comprehensive analyses ...

The authors noted the limitations of the study. Most importantly, use of Epic and other EHRs does not easily allow for tracking of care outside of a network or health care system. This is particularly ...

PURPOSEMicrosatellite instability–high (MSI-H) advanced gastric or esophagogastric junction cancer (AGC), accounting for 5%-6% of all AGC cases, has shown an enhanced responsiveness to immunotherapy.

Despite potential benefits to the field and interest by individual patients, oncology clinical trials continue to struggle with low and delayed enrollment, as well as a lack of racial, ethnic, age, ...

Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This ...

Radiation dose escalation for locally advanced non–small cell lung cancer (LA-NSCLC) has been challenged by toxicity concerns. The Scandinavian phase III multicenter dose-escalation trial NARLAL2 ...

PURPOSESurvival for patients with melanoma has recently improved. The propensity of melanoma to metastasize to the brain remains a common and serious feature of this disease. The purposes of this ...

The cyclin-dependent kinase 4/6 (CDK4/6) inhibitors palbociclib, abemaciclib, and ribociclib each showed a significant or strong trend to improve overall survival (OS) when given as second-line ...

PURPOSENewly approved drugs and combinations treating multiple myeloma (MM) have resulted in substantial improvements in patients' survival. To deliver rapid access to newer therapies, an earlier end ...

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...